Professor

Shehata

Biography

Professor Hassan Shehata is a dedicated NHS clinician, researcher, and global health leader with extensive experience in clinical leadership, strategic vision, and advocacy at local, national, and international levels. Currently serving as the Senior and Global Health Vice President of the Royal College of Obstetricians and Gynaecologists (RCOG), he champions workforce transformation, patient safety initiatives,
and equitable healthcare access.

Throughout his career, Professor Shehata has demonstrated strong leadership in clinical governance, stakeholder engagement, and international partnerships, with a deep commitment to advancing women’s health. Notably, he led the development of the RCOG’s Advocacy and Training Toolkit addressing the medicalisation of Female Genital Mutilation (FGM), reinforcing the College’s commitment to inclusive, patient-centred care. His leadership prioritises clinician well-being, focusing on initiatives to combat burnout, enhance workplace flexibility, and improve retention and recruitment.

He advocates for consultant-led, multidisciplinary team-based care to optimise clinical outcomes and decision-making, actively recognising the valuable contributions of consultants, trainees,
and SAS/LED doctors.

As the Clinical Lead for the South-West London and Surrey Heartlands Maternal Medicine Network, Professor Shehata established multidisciplinary teams, robust clinical pathways, and equitable access to care for women with complex medical conditions. His role as a Consultant Obstetrician and Maternal Medicine subspecialist provides him with deep insights into diverse healthcare needs across cultures and socioeconomic contexts. He is passionately committed to equality, diversity, and inclusion, actively addressing differential attainment, gender pay disparities, and workforce inequities. His international collaborations have enhanced maternal and gynaecological healthcare in Nigeria and Bangladesh, and he has introduced obstetric emergency training programmes in Sudan, Egypt, and Jordan, including the successful ALSO course in Sudan and the Saving Maternal Lives course in Jordan.

With over 100 peer-reviewed publications, 10 book chapters,
and one edited book—including influential studies in the
New England Journal of Medicine, The Lancet, and the British Medical Journal—his research has significantly shaped clinical practice in maternal medicine, recurrent miscarriage, obesity, diabetes, renal disease, and obstetric cholestasis. He has contributed to national and international policy and guidelines through various committees, including CEMACE, RSM, BMA, BMFMS, and NICE.

Professor Shehata is dedicated to maintaining the RCOG’s global leadership in healthcare policy, education, and advocacy, serving its diverse membership and upholding its social responsibilities. Known as an influential and structured leader, he is committed to solutions that enhance care quality, empower the workforce, and advance global women’s health.

Qualifications

MB BS (Hons)

University of Khartoum

1988

MRCOG

Royal College of Obstetricians & Gynaecologists

1997

MRCPI

Royal College of Physicians of Ireland

1998

FRCOG

Royal College of Obstetricians & Gynaecologists

2009

FRCPI

Royal College of Physicians of Ireland​

2010

Current Roles

Work for RCOG

Since December 2022, Professor Shehata has served as the Senior and Global Health Vice President of the RCOG, where he advocates for women’s health equity on a global scale. He drives policy, education, and access to care, with a particular emphasis on addressing ethnic health disparities and promoting sexual and reproductive health rights. Through his efforts, he has successfully generated approximately £350,000 in grant funding to support the RCOG Essential Gynaecology Skills Programme in Nigeria. Additionally, he has developed crucial collaborations with overseas organisations, enhancing global women’s health initiatives while working closely with FIGO, EBCOG, FOGSI, and AICC. His commitment to improving stakeholder representation in RCOG guideline development is complemented by his work in establishing observership programmes in fetal medicine, maternal medicine, and urogynaecology for post-MRCOG doctors from Sri Lanka, Pakistan, and Nigeria, thereby expanding training opportunities within UK subspecialty units.

In his broader roles within the RCOG, Professor Shehata serves as a Senior Officer and Council Member, as well as a member of the Board of Trustees. He chairs the Global Health Board and has successfully led the RCOG World Congress meetings in London (2023) and Muscat (2024), while preparing for the upcoming London (2025) congress. He oversees all RCOG events and meetings, carefully evaluating their quality and participant feedback to ensure they align with current training curricula and CPD requirements. Furthermore, he co-chairs the MTI Taskforce Workstream 2, where he develops initiatives that address racism and differential attainment, including webinars and coaching programmes. He also chairs the “Gynaecology Health Matters” programme in Asia and Sub-Saharan Africa and leads the Anti-Medicalisation of FGM Ethical and Advocacy Toolkit.

In terms of external representation, Professor Shehata serves on the PRSB Advisory Board, providing his expertise in standards development, and is an active member of the Maternity and Neonatal Programme Board Committee, contributing to the enhancement of safety and quality in maternity care across England. He represented the College during the Parliamentary Women and Equality Committee’s recent enquiry on FGM on 5th March 2025 and serves as the RCOG ECOSOC Lead Representative at the Commission on the Status of Women (CSW 69th session, New York – March 2025), where he leads advocacy efforts to advance women’s health and rights on a global scale.

Professional Journey

Clinical Experience

Professor Shehata has extensive
clinical experience as an Obstetrician
and Gynaecologist and has served as a Lead Maternal Medicine Consultant since 2001.

Quality Improvement

Throughout his career, Professor Shehata has developed innovative models of care that have gained national and international recognition.

Leadership

In leadership positions, Professor Shehata served as Clinical Director from 2009 to 2015 and Division Director from 2015 to 2018.

Other External Roles

Professor Shehata has held various external roles, including serving as a CEMACH Maternal Death Assessor
from 2009 to 2010.

Education

Professor Shehata has served as an MRCOG examiner for the MRCOG Part 1, 2, and 3 exams on numerous occasions, conducted on both virtual platforms and in person.

Global Health

In the realm of global health, Professor Shehata leads initiatives aimed at influencing health policy and improving sexual and reproductive healthcare worldwide.

Research

Professor Shehata served as the Deputy Director of Research and Development at Epsom & St Helier University Hospitals from 2016 to 2019. He has a strong research background with over 100 peer-reviewed publications, including significant contributions to the New England Journal of Medicine,
The Lancet, and the British Medical Journal. His research interests include recurrent miscarriages, obesity, diabetes, renal disease, and obstetric cholestasis.

impactful publications include

Previous RCOG Roles

Professor Shehata served as the MENA Region International Fellows Representative on the RCOG Council from 2016 to 2022, playing a pivotal role in enhancing communication between the MENA Region International Representatives, Liaison Groups, and the College. During his tenure as the RCOG MENA Region Webinars Lead from 2020 to 2021, he successfully organised a series of webinars that were conducted almost weekly, achieving impressive attendance figures ranging from 1,200 to 3,000 participants per session.

From 2013 to 2016, Professor Shehata acted as the RCOG Gulf Ambassador, during which he significantly strengthened partnerships, fostered collaboration, and promoted training and education initiatives across Gulf countries. His efforts contributed to a marked increase in the RCOG’s presence and influence within the region. Furthermore, he was an active participant in the RCOG Workforce Task Group from 2008 to 2009, where he engaged in strategic initiatives focused on workforce sustainability and played a key role in shaping policies aimed at recruitment, retention, and well-being to effectively address future healthcare demands.

Clinical Experience

Professor Shehata has extensive clinical experience as an Obstetrician and Gynaecologist and currently serves as a Lead Maternal Medicine Consultant since 2001. He possesses specialist expertise as a senior clinician, trainer, and academic in areas such as recurrent miscarriage and maternal medicine, including obesity and diabetes services. He is recognised as an expert in pre-conception counselling for high-risk obstetric patients, managing a diverse range of conditions—including diabetes, antiphospholipid syndrome (APS), thyroid disorders, neurological issues, cardiovascular diseases, respiratory conditions, and renal complications—through individualised assessments and treatment plans. The maternal medicine centre he leads is accredited for RCOG training and is recognised as a Co-Hub for the South West London and Surrey Heartlands Maternal Medicine Network.

Quality Improvement

Throughout his career, Professor Shehata has developed innovative models of care that have gained national and international recognition. He founded the South London and Surrey Recurrent Miscarriage Clinic in 2002, which has achieved national acclaim for its pioneering research and management approaches. In 2001, he established the Obstetric Medicine Clinic, where he has mentored trainees and implemented evidence-based protocols. He has also developed obstetric specialist clinics that enhance care quality through expert-led services and co-founded the regional Renal/Obstetric service, which provides specialised preconception and antenatal care. Additionally, he co-founded and led the internationally recognised “Saving Mothers and Babies Lives” and ALSO courses, significantly improving maternal outcomes on a global scale.

Leadership

In leadership positions, Professor Shehata served as Clinical Director from 2009 to 2015 and Division Director from 2015 to 2018. During his tenure, he facilitated the appointment of ten new consultants, enabling the trust to meet the RCOG recommendations for labour ward consultant cover. He successfully led the initiative to achieve Baby-Friendly Initiative (BFI) level 1 status, the highest rating in the sector, while also reducing the caesarean section rate from 35% to 27% while maintaining excellent perinatal outcomes. He achieved CNST level 3 in 2014 through collaborative work across specialties, including the revision of complex obstetric care guidelines. In his current role as Clinical Director of the Maternal Medicine Network for South West London and Surrey Heartlands since 2021, he is responsible for the day-to-day operation of services, job planning, appraisals, strategic planning, and governance structure development, as well as for integrating regional maternal medicine services and managing complex cases at the Co-Hubs to ensure timely and appropriate care.

Other External Roles

Professor Shehata has held various external roles, including serving as a CEMACH Maternal Death Assessor from 2009 to 2010, and as a member of the NICE IOL Guidelines Development Group during two periods (2007-2008, 2013-2014). He was also a National Structure Framework Diabetes Assessor from 2003 to 2004 and served on the Executive Committee of Physicians for Human Rights (PHR) from 1996 to 2001. Additionally, he participated in a local BMA advisory committee from 2018 to 2022. Currently, he is a member of the Maternal Reducing Inequalities Care Bundle (MRCIB) Steering Group, providing strategic oversight to ensure alignment with the London Regional Maternity Team’s vision for achieving equity in maternity outcomes. He is also a member of the FIGO Women’s Health & Technology Committee, advocating for equitable innovation and digitalisation in women’s health.

Education

Professor Shehata has served as an MRCOG examiner for the MRCOG Part 1, 2, and 3 exams on numerous occasions, including the Part 3 exam conducted on both virtual platforms and in person. He is closely associated with the Medical Trainees Initiative (MTI) scheme and Global Health trainees since 2022, actively participating in MTI activities within the RCOG and utilising peer-to-peer platforms to maintain effective communication. As the co-director of the Saving Mothers and Babies Lives Training Course in Jordan since 2022, he has led initiatives to enhance skills in managing obstetric emergencies, successfully training approximately 150 healthcare professionals to date. Additionally, he serves as the Director of the Anti-Medicalisation FGM Ethical and Advocacy Toolkit since 2023, where he developed a specialised training program to equip healthcare professionals with the knowledge and skills to recognise the harms of FGM/C and advocate for its eradication within their communities.

Global Health

In the realm of global health, Professor Shehata leads initiatives aimed at influencing health policy and improving sexual, reproductive, and post-reproductive healthcare worldwide. He advocates for women’s health rights, working diligently to increase healthcare access and amplify the voices of underserved women, particularly in relation to FGM, obesity, and ethnic health disparities. He developed the RCOG FGM Advocacy & Training Toolkit to combat the medicalisation of FGM and support global education efforts. Professor Shehata is committed to assisting RCOG’s global members by adapting guidelines to local contexts and ensuring the relevance of the MRCOG qualification in diverse healthcare settings. He actively drives the RCOG’s philanthropic role by expanding strategic global health projects to maximize impact.

Publication History

1.

Severe hyponatremia in obstetrics: Presentations and outcome. Retrospective cohort over 10 years.

Elbarbary N, Datta T, Viswanatha R, Johnstone H, Shehata H, Ganapathy R.
Int J Gynaecol Obstet. 2025 Mar;168(3):1026-1030. doi: 10.1002/ijgo.15939. Epub 2024 Oct 24.

PMID: 39445579

2.

Pregnancy outcomes for women with pre-existing renal disease and the role of a dedicated joint maternal medicine and renal clinic: A retrospective cohort study.

Wildridge B, Makanjuola D, Johnson A, Ganapathy R, Mountford L, Bell C, Odogwu J, Shehata H.
Int J Gynaecol Obstet. 2024 Sep;166(3):1086-1091. doi: 10.1002/ijgo.15492. Epub 2024 Mar 22.

PMID: 38520087

3.

Managing couples with recurrent miscarriage: A narrative review and practice recommendations.

Ali A, Elfituri A, Doumouchtsis SK, Zini ME, Jan H, Ganapathy R, Divakar H, Hod M, Shehata H.
Int J Gynaecol Obstet. 2024 Feb;164(2):499-503. doi: 10.1002/ijgo.14971. Epub 2023 Jul 10.

PMID: 37431204 Review.

4.

FIGO Good Practice Recommendations on the use of progesterone in the management of recurrent first-trimester miscarriage.

Shehata H, Elfituri A, Doumouchtsis SK, Zini ME, Ali A, Jan H, Ganapathy R, Divakar H, Hod M.
Int J Gynaecol Obstet. 2023 Apr;161 Suppl 1:3-16. doi: 10.1002/ijgo.14717.

PMID: 36958854 No abstract available.

5.

Thrombophilia screening in women with recurrent first trimester miscarriage: is it time to stop testing? – a cohort study and systematic review of the literature.

Shehata H, Ali A, Silva-Edge M, Haroon S, Elfituri A, Viswanatha R, Jan H, Akolekar R.
BMJ Open. 2022 Jul 13;12(7):e059519. doi: 10.1136/bmjopen-2021-059519.

PMID: 35831047 Free PMC article.

6.

Sperm DNA fragmentation is a novel biomarker for early pregnancy loss.

Haddock L, Gordon S, Lewis SEM, Larsen P, Shehata A, Shehata H.
Reprod Biomed Online. 2021 Jan;42(1):175-184. doi: 10.1016/j.rbmo.2020.09.016. Epub 2020 Sep 22.

PMID: 33082108

7.

Recurrent miscarriage: evidence to accelerate action.

Coomarasamy A, Dhillon-Smith RK, Papadopoulou A, Al-Memar M, Brewin J, Abrahams VM, Maheshwari A, Christiansen OB, Stephenson MD, Goddijn M, Oladapo OT, Wijeyaratne CN, Bick D, Shehata H, Small R, Bennett PR, Regan L, Rai R, Bourne T, Kaur R, Pickering O, Brosens JJ, Devall AJ, Gallos ID, Quenby S.
Lancet. 2021 May 1;397(10285):1675-1682. doi: 10.1016/S0140-6736(21)00681-4. Epub 2021 Apr 27.

PMID: 33915096

8.

Metformin use in obese mothers is associated with improved cardiovascular profile in the offspring.

Panagiotopoulou O, Syngelaki A, Georgiopoulos G, Simpson J, Akolekar R, Shehata H, Nicolaides K, Charakida M.
Am J Obstet Gynecol. 2020 Aug;223(2):246.e1-246.e10. doi: 10.1016/j.ajog.2020.01.054. Epub 2020 Feb 1.

PMID: 32017923 Clinical Trial.

9.

Metformin in Pregnancy Study (MiPS): protocol for a systematic review with individual patient data meta-analysis.

Mousa A, Løvvik T, Hilkka I, Carlsen SM, Morin-Papunen L, Tertti K, Rönnemaa T, Syngelaki A, Nicolaides K, Shehata H, Burden C, Norman JE, Rowan J, Dodd JM, Hague W, Vanky E, Teede HJ.
BMJ Open. 2020 May 21;10(5):e036981. doi: 10.1136/bmjopen-2020-036981.

PMID: 32444434 Free PMC article.

10.

Visceral fat mass as a novel risk factor for predicting gestational diabetes in obese pregnant women.

Balani J, Hyer SL, Shehata H, Mohareb F.
Obstet Med. 2018 Sep;11(3):121-125. doi: 10.1177/1753495X17754149. Epub 2018 Mar 14.

PMID: 30214477 Free PMC article.

11.

Metformin in Pregnancy: Mechanisms and Clinical Applications.

Hyer S, Balani J, Shehata H.
Int J Mol Sci. 2018 Jul 4;19(7):1954. doi: 10.3390/ijms19071954.

PMID: 29973490 Free PMC article. Review.

12.

Association between insulin resistance and preeclampsia in obese non-diabetic women receiving metformin.

Balani J, Hyer S, Syngelaki A, Akolekar R, Nicolaides KH, Johnson A, Shehata H.
Obstet Med. 2017 Dec;10(4):170-173. doi: 10.1177/1753495X17725465. Epub 2017 Oct 16.

PMID: 29225676 Free PMC article.

13.

Managing Recurring Obstetric Cholestasis With Metformin.

Elfituri A, Ali A, Shehata H.
Obstet Gynecol. 2016 Dec;128(6):1320-1323. doi: 10.1097/AOG.0000000000001748.

PMID: 27824743

14.

Metformin versus Placebo in Obese Pregnant Women without Diabetes.

Balani J, Hyer S, Shehata H.
N Engl J Med. 2016 Jun 23;374(25):2502. doi: 10.1056/NEJMc1603067.

PMID: 27332917 No abstract available.

15.

Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.

Syngelaki A, Nicolaides KH, Balani J, Hyer S, Akolekar R, Kotecha R, Pastides A, Shehata H.
N Engl J Med. 2016 Feb 4;374(5):434-43. doi: 10.1056/NEJMoa1509819.

PMID: 26840133 Clinical Trial.

16.

The importance of visceral fat mass in obese pregnant women and relation with pregnancy outcomes.

Balani J, Hyer S, Johnson A, Shehata H.
Obstet Med. 2014 Mar;7(1):22-5. doi: 10.1177/1753495X13495192. Epub 2013 Aug 8.

PMID: 27512414 Free PMC article.

17.

Natural killer cells and their activation status in normal pregnancy.

Mosimann B, Wagner M, Shehata H, Poon LC, Ford B, Nicolaides KH, Bansal AS.
Int J Reprod Med. 2013;2013:906813. doi: 10.1155/2013/906813. Epub 2013 Mar 27.

PMID: 25763390 Free PMC article.

18.

Gastrointestinal and liver disease in pregnancy.

Boregowda G, Shehata HA.
Best Pract Res Clin Obstet Gynaecol. 2013 Dec;27(6):835-53. doi: 10.1016/j.bpobgyn.2013.07.006.

PMID: 24207084 Review.

19.

Uric acid: is it time to give up routine testing in management of pre-eclampsia?

Talaulikar VS, Shehata H.
Obstet Med. 2012 Sep;5(3):119-23. doi: 10.1258/om.2011.110075. Epub 2012 Mar 29.

PMID: 27582868 Free PMC article.

20.

Pregnancy outcomes after metformin treatment for gestational diabetes: a case-control study.

Balani J, Hyer S, Johnson A, Shehata H.
Obstet Med. 2012 Jun;5(2):78-82. doi: 10.1258/om.2012.110092. Epub 2012 Apr 23.

PMID: 27579140 Free PMC article.

21.

Advances in the understanding and management of haematological disorders associated with pregnancy.

Shehata H.
Best Pract Res Clin Obstet Gynaecol. 2012 Feb;26(1):1-2. doi: 10.1016/j.bpobgyn.2011.10.011. Epub 2011 Nov 16.

PMID: 22094325 No abstract available.

22.

Pregnancy-associated atypical haemolytic uraemic syndrome in the postpartum period: a case report and review of the literature.

Egbor M, Johnson A, Harris F, Makanjoula D, Shehata H.
Obstet Med. 2011 Jun;4(2):83-5. doi: 10.1258/om.2011.100059. Epub 2011 Jun 9.

PMID: 27582861 Free PMC article.

23.

Early prediction of preeclampsia in high-risk women.

Shaker OG, Shehata H.
J Womens Health (Larchmt). 2011 Apr;20(4):539-44. doi: 10.1089/jwh.2010.2378. Epub 2011 Mar 17.

PMID: 21413896

24.

Recurrent miscarriage and autoimmunity.

Bansal AS, Bajardeen B, Shehata H, Thum MY.
Expert Rev Clin Immunol. 2011 Jan;7(1):37-44. doi: 10.1586/eci.10.84.

PMID: 21162648 Review.

25.

Serum cystatin is not a marker of glomerular filtration rate in pregnancy.

Bramham K, Makanjuola D, Hussein W, Cafful D, Shehata H.
Obstet Med. 2009 Sep;2(3):121-2. doi: 10.1258/om.2009.090019. Epub 2009 Sep 1.

PMID: 27582826 Free PMC article.

26.

Pregnancy outcomes in women with gestational diabetes treated with metformin or insulin: a case-control study.

Balani J, Hyer SL, Rodin DA, Shehata H.
Diabet Med. 2009 Aug;26(8):798-802. doi: 10.1111/j.1464-5491.2009.02780.x.

PMID: 19709150

27.

Uterus didelphys in mosaic trisomy 8 patient: Management and fertility issues.

Shehata H, Gharaibeh A, Bramham K, Lamb G, Makanjuola D.
Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):91-2. doi: 10.1016/j.ejogrb.2008.07.011. Epub 2008 Oct 8.

PMID: 18845375 No abstract available.

28.

Diabetes in pregnancy: a review of current evidence.

Kapoor N, Sankaran S, Hyer S, Shehata H.
Curr Opin Obstet Gynecol. 2007 Dec;19(6):586-90. doi: 10.1097/GCO.0b013e3282f20aad.

PMID: 18007138 Review.

29.

Menorrhagia and bleeding disorders.

El-Hemaidi I, Gharaibeh A, Shehata H.
Curr Opin Obstet Gynecol. 2007 Dec;19(6):513-20. doi: 10.1097/GCO.0b013e3282f1ddbe.

PMID: 18007127 Review.

30.

Successful pregnancy in a patient with end-stage renal failure secondary to HIV nephropathy on peritoneal dialysis.

Asgari E, Bramham K, Shehata H, Makanjuola D.
Nephrol Dial Transplant. 2007 Dec;22(12):3671. doi: 10.1093/ndt/gfm280. Epub 2007 Sep 11.

PMID: 17848397 No abstract available.

31.

The relationship of systemic TNF-alpha and IFN-gamma with IVF treatment outcome and peripheral blood NK cells.

Thum MY, Abdalla HI, Bhaskaran S, Harden EL, Ford B, Sumar N, Shehata H, Bansal A.
Am J Reprod Immunol. 2007 Mar;57(3):210-7. doi: 10.1111/j.1600-0897.2006.00465.x.

PMID: 17295900

32.

The effect of serum concentration of leukaemia inhibitory factor on in vitro fertilization treatment outcome.

Thum MY, Abdalla HI, Bhaskaran S, Harden EL, Ford B, Sumar N, Shehata H, Bansal AS.
Am J Reprod Immunol. 2006 Jan;55(1):76-80. doi: 10.1111/j.1600-0897.2005.00328.x.

PMID: 16364015

33.

Simple enumerations of peripheral blood natural killer (CD56+ NK) cells, B cells and T cells have no predictive value in IVF treatment outcome.

Thum MY, Bhaskaran S, Bansal AS, Shehata H, Ford B, Sumar N, Abdalla HI.
Hum Reprod. 2005 May;20(5):1272-6. doi: 10.1093/humrep/deh774. Epub 2005 Apr 13.

PMID: 15829490

34.

An increase in the absolute count of CD56dimCD16+CD69+ NK cells in the peripheral blood is associated with a poorer IVF treatment and pregnancy outcome.

Thum MY, Bhaskaran S, Abdalla HI, Ford B, Sumar N, Shehata H, Bansal AS.
Hum Reprod. 2004 Oct;19(10):2395-400. doi: 10.1093/humrep/deh378. Epub 2004 Aug 19.

PMID: 15319390

35.

Use of cyclosporin in pregnancy.

Jayaprakash A, Gould S, Lim AG, Shehata HA.
Gut. 2004 Sep;53(9):1386-7. doi: 10.1136/gut.2003.036103.

PMID: 15306605 Free PMC article. No abstract available.

36.

Obstetric complications of twin pregnancies.

Rao A, Sairam S, Shehata H.
Best Pract Res Clin Obstet Gynaecol. 2004 Aug;18(4):557-76. doi: 10.1016/j.bpobgyn.2004.04.007.

PMID: 15279817 Review.

37.

Respiratory disease in pregnancy.

Bhide A, Shehata HA.
Curr Obstet Gynaecol. 2004 Jun;14(3):175-182. doi: 10.1016/j.curobgyn.2004.02.002. Epub 2004 May 6.

PMID: 32288339 Free PMC article.

38.

Neurological disorders in pregnancy.

Shehata HA, Okosun H.
Curr Opin Obstet Gynecol. 2004 Apr;16(2):117-22. doi: 10.1097/00001703-200404000-00004.

PMID: 15017339 Review.

39.

Drugs in pregnancy. Drugs to avoid.

Shehata HA, Nelson-Piercy C.
Best Pract Res Clin Obstet Gynaecol. 2001 Dec;15(6):971-86. doi: 10.1053/beog.2001.0241.

PMID: 11800536 Review.

40.

Internal jugular vein thrombosis after assisted conception therapy.

Arya R, Shehata HA, Patel RK, Sahu S, Rajasingam D, Harrington KF, Nelson-Piercy C, Parsons JH.
Br J Haematol. 2001 Oct;115(1):153-5. doi: 10.1046/j.1365-2141.2001.03081.x.

PMID: 11722427

41.

Management of pregnancy in antiphospholipid syndrome.

Shehata HA, Nelson-Piercy C, Khamashta MA.
Rheum Dis Clin North Am. 2001 Aug;27(3):643-59. doi: 10.1016/s0889-857x(05)70226-x.

PMID: 11534266 Review.

42.

Fasciitis: a rare complication of Burch colposuspension.

Georgiou M, Shehata HA, Chaliha C, Byrne PD, McWhinney NA, Gough PM.
BJOG. 2001 Feb;108(2):227-9. doi: 10.1111/j.1471-0528.2001.00027.x.

PMID: 11236127 No abstract available.

43.

Towards the modern management of ectopic pregnancy: a complete audit cycle of practice in a London teaching hospital.

Oyelese KO, Shehata H, Hussain S, Manyonda I.
J Obstet Gynaecol. 1999 May;19(3):276-9. doi: 10.1080/01443619965066.

PMID: 15512295

44.

Red cell distribution width (RDW) changes in pregnancy.

Shehata HA, Ali MM, Evans-Jones JC, Upton GJ, Manyonda IT.
Int J Gynaecol Obstet. 1998 Jul;62(1):43-6. doi: 10.1016/s0020-7292(98)00069-1.

PMID: 9722124